Literature DB >> 23500147

Design, production, and characterization of a single-chain variable fragment (ScFv) derived from the prostate specific membrane antigen (PSMA) monoclonal antibody J591.

Stephanie A Parker1, Ines Lopez-Calleja Diaz, Kyle A Anderson, Carl A Batt.   

Abstract

A single chain variable fragment (J591 ScFv) that recognizes the extracellular glyco-protein prostate specific membrane antigen (PSMA) was designed, constructed, and expressed in Pichia pastoris. Construction of the J591 ScFv was based on the reported complementarity-determining region (CDR) of the PSMA specific J591 monoclonal antibody (mAb). The nucleotide sequence encoding the J591-derived ScFv was codon-optimized for expression in P. pastoris and a 6× his-tag was added to facilitate affinity purification. A down-scale 2L methanol-induced P. pastoris fermentation yielded 330mg of total protein following a 96h induction. Following Immobolized Metal Affinity Chromatography, functionality of the J591 ScFv was confirmed via Western blot, immunoblot, binding studies, and flow cytometry analysis. The J591 ScFv showed binding affinity and specificity to cell extracts containing PSMA and PSMA-expressing prostate cancer cells. Our results demonstrate that functional J591 ScFv can be produced in P. pastoris for use in diagnostic and targeted therapeutic applications.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23500147     DOI: 10.1016/j.pep.2013.02.016

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  9 in total

Review 1.  A Review on the Current State and Future Perspectives of [99mTc]Tc-Housed PSMA-i in Prostate Cancer.

Authors:  Sara Brunello; Nicola Salvarese; Debora Carpanese; Carolina Gobbi; Laura Melendez-Alafort; Cristina Bolzati
Journal:  Molecules       Date:  2022-04-19       Impact factor: 4.927

2.  Production of Therapeutic Single-Chain Variable Fragments (ScFv) in Pichia pastoris.

Authors:  Laia Montoliu-Gaya; Sandra Villegas
Journal:  Methods Mol Biol       Date:  2022

3.  scFv from Antibody That Mimics gp43 Modulates the Cellular and Humoral Immune Responses during Experimental Paracoccidioidomycosis.

Authors:  Grasielle Pereira Jannuzzi; Aldo Henrique F P Tavares; Gilberto Hideo Kaihami; José Roberto Fogaça de Almeida; Sandro Rogério de Almeida; Karen Spadari Ferreira
Journal:  PLoS One       Date:  2015-06-19       Impact factor: 3.240

4.  Antiproliferative and apoptotic effects of a specific antiprostate stem cell single chain antibody on human prostate cancer cells.

Authors:  Foroogh Nejatollahi; Soghra Abdi; Mahdi Asgharpour
Journal:  J Oncol       Date:  2013-12-10       Impact factor: 4.375

5.  A 99mTc-labelled scFv antibody fragment that binds to prostate-specific membrane antigen.

Authors:  Saima Nawaz; Gregory E D Mullen; Philip J Blower; James R Ballinger
Journal:  Nucl Med Commun       Date:  2017-08       Impact factor: 1.690

6.  Cell growth inhibition and apoptotic effects of a specific anti-RTFscFv antibody on prostate cancer, but not glioblastoma, cells.

Authors:  Foroogh Nejatollahi; Payam Bayat; Bahareh Moazen
Journal:  F1000Res       Date:  2017-02-17

Review 7.  Recombinant antibody production evolves into multiple options aimed at yielding reagents suitable for application-specific needs.

Authors:  Ario de Marco
Journal:  Microb Cell Fact       Date:  2015-09-02       Impact factor: 5.328

8.  A novel anti-PSMA human scFv has the potential to be used as a diagnostic tool in prostate cancer.

Authors:  Donghui Han; Jieheng Wu; Yueheng Han; Ming Wei; Sen Han; Ruihe Lin; Ziyong Sun; Fa Yang; Dian Jiao; Pin Xie; Lingling Zhang; An-Gang Yang; Aizhi Zhao; Weihong Wen; Weijun Qin
Journal:  Oncotarget       Date:  2016-09-13

9.  Engineered Fragments of the PSMA-Specific 5D3 Antibody and Their Functional Characterization.

Authors:  Zora Novakova; Nikola Belousova; Catherine A Foss; Barbora Havlinova; Marketa Gresova; Gargi Das; Ala Lisok; Adam Prada; Marketa Barinkova; Martin Hubalek; Martin G Pomper; Cyril Barinka
Journal:  Int J Mol Sci       Date:  2020-09-12       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.